These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 570724)

  • 21. Fetal methylazoxymethanol acetate-induced lesions cause reductions in dopamine receptor-mediated catalepsy and stereotypy.
    Sanberg PR; Pevsner J; Autuono PG; Coyle JT
    Neuropharmacology; 1985 Nov; 24(11):1057-62. PubMed ID: 4080104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity.
    Creese I; Burt DR; Snyder SH
    Science; 1977 Aug; 197(4303):596-8. PubMed ID: 877576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychomotor performance in the senescent rodent: reduction of deficits via striatal dopamine receptor up-regulation.
    Joseph JA; Bartus RT; Clody D; Morgan D; Finch C; Beer B; Sesack S
    Neurobiol Aging; 1983; 4(4):313-9. PubMed ID: 6687001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
    Gnegy M; Uzunov P; Costa E
    J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
    [No Abstract]   [Full Text] [Related]  

  • 26. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of duration of haloperidol treatment on DA receptor supersensitization in aging C57BL/6J mice.
    Randall PK; Severson JA; Hurd SM; McClure WO
    Brain Res; 1985 Apr; 333(1):85-95. PubMed ID: 4039618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral supersensitivity to beta-phenylethylamine after chronic administration of haloperidol.
    Stoff DM; Jeste DV; Gillin JC; Moja EA; Cohen L; Stauderman KA; Wyatt RJ
    Biol Psychiatry; 1984 Jan; 19(1):101-6. PubMed ID: 6538440
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of gestational and neonatal styrene exposure on dopamine receptors.
    Zaidi NF; Agrawal AK; Srivastava SP; Seth PK
    Neurobehav Toxicol Teratol; 1985; 7(1):23-8. PubMed ID: 4039799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of haloperidol and apomorphine treatment on dopamine receptors in pituitary and striatum.
    Friend WC; Brown GM; Jawahir G; Lee T; Seeman P
    Am J Psychiatry; 1978 Jul; 135(7):839-41. PubMed ID: 665797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postsynaptic receptors are not essential for dopaminergic feedback regulation.
    Di Chiara G; Porceddu ML; Fratta W; Gessa GL
    Nature; 1977 May; 267(5608):270-2. PubMed ID: 865621
    [No Abstract]   [Full Text] [Related]  

  • 33. Aging and the regulation of striatal dopaminergic mechanisms in mice.
    Randall PK; Severson JA; Finch CE
    J Pharmacol Exp Ther; 1981 Dec; 219(3):695-700. PubMed ID: 7197719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of insulin hypoglycemia on central dopaminergic structures of the rat.
    Kleinrok Z; Ossowska G; Stelmasiak M; Juszkiewicz M
    Pol J Pharmacol Pharm; 1983; 35(6):489-95. PubMed ID: 6377282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The brain's dopamine receptor: labeling with (3H) dopamine and (3H) haloperidol.
    Snyder SH; Creese I; Burt DR
    Psychopharmacol Commun; 1975; 1(6):663-73. PubMed ID: 1241457
    [No Abstract]   [Full Text] [Related]  

  • 37. Apomorphine-haloperidol interactions: different types of antagonism in cortical and subcortical brain regions.
    Bacopoulos NG; Roth RH
    Brain Res; 1981 Feb; 205(2):313-9. PubMed ID: 7470869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postnatal haloperidol eliminates the deficit in circling behavior produced by prenatal exposure to the same drug.
    Wolansky MJ; Soiza-Reilly M; Fossati M; Azcurra JM
    Neurotoxicol Teratol; 2004; 26(4):561-9. PubMed ID: 15203178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of chronic haloperidol, thioridazine and zotepine treatment on apomorphine elicited stereotypic behavior and 3H-spiroperidol binding sites in the striatum of the rat.
    Lai HC; Carino MA; Horita A
    Proc West Pharmacol Soc; 1981; 24():5-6. PubMed ID: 6114496
    [No Abstract]   [Full Text] [Related]  

  • 40. Dopamine antagonist binding increases in two behaviorally distinct striatal denervation syndromes.
    Thal L; Mishra RK; Gardner EL; Horowitz SG; Varmuza S; Makman MH
    Brain Res; 1979 Jul; 170(2):381-6. PubMed ID: 572733
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.